Conclusions : Isoflavone treatments exert a moderately beneficial effect against  estrogen-deficient bone loss in women .
The effect appears dependent on whether isoflavone treatments are in aglycone form ; we conclude that beneficial effects against bone loss may be enhanced for isoflavone aglycones
Background : Age-related estrogen deficiency leads to accelerated bone resorption .
There is evidence that , through selective estrogen receptor modulation , isoflavones may exert beneficial effects against  estrogen-deficient bone loss .
Isoflavone aglycones show higher bioavailability than their glycosidic counterparts and thus may have greater potency .
Objective : To summarize evidence , we executed a systematic review and meta- analysis examining isoflavone therapies and bone mineral density ( BMD ) loss in peri- and postmenopausal women .
Hormone therapy and physical function change among older women in the Women's Health Initiative: a randomized controlled trial
Objective : Although estrogen may be linked to biological pathways that maintain higher physical function , the evidence is derived mostly from observational epidemiology and therefore has numerous limitations . We examined whether hormone therapy affected physical function in women 65 to 79 years of age at enrollment . Methods : This study involves an analysis of the Women 's Health Initiative r and omized controlled trials of hormone therapy in which 922 nondisabled women who had previous hysterectomies were r and omized to receive estrogen therapy or a placebo and 1,458 nondisabled women with intact uteri were r and omized to receive estrogen + progestin therapy or a placebo . Changes in physical function were analyzed for treatment effect , and subgroup differences were evaluated . All women completed performance-based measures of physical function ( grip strength , chair st and s , and timed walk ) at baseline . These measures were repeated after 1 , 3 , and 6 years . Results : Overall , participants ' grip strength declined by 12.0 % , chair st and s declined by 3.5 % , and walk pace slowed by 11.4 % in the 6 years of follow-up ( all P values < 0.0001 ) . Hormone therapy , as compared with placebo , was not associated with an increased or decreased risk of decline in physical function in either the intention-to-treat analyses or in analyses restricted to participants who were compliant in taking study pills . Conclusions : Hormone therapy provided no overall protection against functional decline in nondisabled postmenopausal women 65 years or older in 6 years of follow-up . This study did not address the influence of hormone therapy for women of younger ages
Conclusions : Isoflavone treatments exert a moderately beneficial effect against  estrogen-deficient bone loss in women .
The effect appears dependent on whether isoflavone treatments are in aglycone form ; we conclude that beneficial effects against bone loss may be enhanced for isoflavone aglycones
Background : Age-related estrogen deficiency leads to accelerated bone resorption .
There is evidence that , through selective estrogen receptor modulation , isoflavones may exert beneficial effects against  estrogen-deficient bone loss .
Isoflavone aglycones show higher bioavailability than their glycosidic counterparts and thus may have greater potency .
Objective : To summarize evidence , we executed a systematic review and meta- analysis examining isoflavone therapies and bone mineral density ( BMD ) loss in peri- and postmenopausal women .